Ergomed PLC (LSE:ERGO) - Share price - Overview

Stock Report

Ergomed PLC ERGO

Last Price
GBX209.00

Day Change
3.50|1.70%

As of 17/02/2017
16:30:03 GMT | GBX
Minimum 15 Minutes Delay.

Last Close205.50p
Day Range207.00 - 211.00
Mkt Cap84.66Mil
52-Wk Range117.00 - 215.00
Yield %0.00
ISINGB00BN7ZCY67
Volume41,175
P/E33.56
P/S1.99
P/CF227.67

Share Price

Total Returns 17/02/2017

 Chg (%)  
More ...
Ergomed PLC22.22 
FTSE 100 TR GBP1.55
 
Financials
201320142015
More ...
Income Statement
Turnover15.1521.1630.18
Operating Profit1.780.782.07
Net Profit1.550.581.55
Reported EPS5.372.305.20
Balance Sheet
Current Assets5.2310.9213.50
Non Current Assets1.4810.7611.19
Total Assets6.7221.6824.69
Current Liabilities4.805.767.23
Total Liabilities4.816.347.76
Total Equity1.9115.3416.94
Cash Flow
Operating Cash Flow1.470.970.85
Net Change in Cash1.512.63-0.60
Broker Forecasts
Year EndingPre-taxEPSEPSgP/EPEGDPSYld %
More ...
'Broker Forecasts' provides consensus figures based on several brokers' views
20161.223.45-44.6460.62-1.36--
20171.634.2623.5549.062.08--
Director Dealings
TradedActionNotifierPriceAmountValue
More ...
24/05/2016PurchaseStephen Stamp140.00200,000280,000.00
24/05/2016PurchaseMr. Peter George140.00100,000140,000.00
24/05/2016PurchaseDr. Miroslav Reljanovic140.00400,000560,000.00

Company Profile

Ergomed PLC is engaged in providing services to the pharmaceutical industry and develops new drugs. The Company operates in two business divisions namely Services Business and Co-Development Business.

Sector

Biotechnology

Market Position

945 of 1851 Companies

Index

FTSE AIM All Share

Outlook

(17/01/2017) "Unaudited 2016 revenues expected to be approximately £38.0m"

Next Event 31/03/2017

Next prelim announcement
Ratios
CompSecMkt
More ...
PER (E)49.0614.3016.11
Div Yld (E)0.003.764.04
PEG (E)2.08-0.601.59
ROCE33.34202.24107.14
Op Mrgn7.90-12.26-17.07
EPS Grwth23.5540.8828.56
Dividends
PreviousLatest
More ...
Record Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00

Broker Sentiment

Strong Buy0
Buy2
Hold0
Sell0
Strong Sell0
  • Strong Sell
  • Strong Buy
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
More ...
Disclaimer
Directors
More ...
ChairmanMr. Rolf Stahel
Chief Executive OfficerDr. Miroslav Reljanovic
Chief Financial OfficerStephen Stamp
AJ Bell includes AJ Bell Holdings Limited and its wholly owned subsidiaries. AJ Bell Management Limited and AJ Bell Securities Limited are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at Trafford House, Chester Road, Manchester M32 0RS. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2017 Morningstar. All rights reserved.